Ancilia Biosciences harnesses CRISPR technology to develop innovative bacterial therapies that provide immunity against viruses, targeting the virome to enhance the efficacy of beneficial bacteria in treating chronic diseases across various applications, including therapeutics, agriculture, and industrial biotechnology. Their proprietary platforms, Co VE™ and EPIC™, enable the identification and characterization of viruses, positioning Ancilia as a leader in the emerging field of virome-associated therapies.

New York, NY, USA

Ancilia Biosciences

Pharma

Seed

Where scientists and engineers come together to build ventures that matter.

Deep Science Ventures

Explore jobs at our portfolio companies

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Deep Science Ventures Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Deep Science Ventures network as they come up.

You can always update this information later.

Welcome to the Deep Science Ventures talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Deep Science Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Community Job Board